MammaPrint is a genomic test that analyzes the activity of 70 genes in a breast cancer tumor to predict whether the cancer is likely to spread to other parts of the body within 5 to 10 years after diagnosis. Its main purpose is to help determine whether a patient actually needs chemotherapy after surgery or whether hormone therapy alone is enough. The test is FDA-cleared, recommended in both ASCO and NCCN clinical guidelines, and has been validated in one of the largest breast cancer trials ever conducted.
How MammaPrint Works
After a breast tumor is removed through biopsy or surgery, a tissue sample is sent to a laboratory where the test measures the expression levels of 70 specific genes. Gene expression is essentially how active each gene is, producing more or fewer of the proteins that drive cancer behavior. By reading the pattern across all 70 genes at once, MammaPrint generates a genomic risk score that classifies the tumor as either low risk or high risk for distant metastasis, meaning cancer that spreads beyond the breast to organs like the lungs, liver, or bones.
The test works on formalin-fixed, paraffin-embedded tissue, which is the standard way surgical samples are preserved in pathology labs. This means your surgeon doesn’t need to do anything special to collect the sample. The lab uses next-generation sequencing technology to read the gene expression profile and return a result.
Who the Test Is For
MammaPrint is designed for patients with early-stage invasive breast cancer, specifically stages I through III with limited lymph node involvement. The most common candidates are women with hormone receptor-positive, HER2-negative tumors and zero to three positive lymph nodes. These are the patients who face the hardest treatment decision: their cancer has features that could go either way, and traditional clinical factors alone can’t reliably predict whether chemotherapy will make a meaningful difference.
ASCO guidelines specify that MammaPrint is most useful for patients whose clinical risk of recurrence is already considered high based on tumor size, grade, and other standard features. For patients already classified as low clinical risk, the test isn’t recommended because those patients generally don’t benefit from chemotherapy regardless of their genomic score.
What the Results Mean
MammaPrint returns one of two primary classifications: low genomic risk or high genomic risk. A low-risk result suggests the cancer is unlikely to spread and that chemotherapy would add little benefit beyond hormone therapy alone. A high-risk result suggests a greater chance of distant recurrence and that chemotherapy is more likely to be worthwhile. Some reports also include an “ultralow” category for tumors with the most favorable gene profiles.
The distinction matters most for patients caught in the middle. If your oncologist can already tell from traditional pathology that your cancer is aggressive, or conversely that it’s very slow-growing, the genomic test may not change the recommendation. But for the large group of patients where the decision is genuinely uncertain, MammaPrint can tip the balance one way or the other.
The MINDACT Trial: Evidence Behind the Test
The strongest evidence supporting MammaPrint comes from the MINDACT trial, a large randomized study that enrolled 6,693 women aged 18 to 70 with operable early-stage breast cancer across multiple European centers. The trial compared treatment decisions based on traditional clinical risk assessment alone versus decisions informed by MammaPrint’s genomic risk score.
The key finding involved patients whose clinical features suggested high risk but whose MammaPrint results showed low genomic risk. Among those patients who skipped chemotherapy based on the genomic result, 95.1% were alive without distant metastasis at five years. Patients in the same category who did receive chemotherapy had a rate of 96.2%. That difference of roughly one percentage point means the vast majority of these women gained no benefit from chemotherapy and could have been safely spared its side effects.
In practical terms, the MINDACT results suggested that nearly half of women with early-stage breast cancer who would have been told they needed chemotherapy based on clinical factors alone could safely skip it. For those patients, avoiding months of treatment, along with side effects like fatigue, nausea, hair loss, and immune suppression, represents a significant quality-of-life gain with virtually no trade-off in survival.
MammaPrint vs. Oncotype DX
MammaPrint is not the only genomic test used in breast cancer. Oncotype DX, which analyzes 21 genes rather than 70, is another widely used option. Both tests aim to answer the same core question: will this patient benefit from chemotherapy? Both are recommended in major oncology guidelines, and both have been validated in large clinical trials.
The tests differ in their approach. MammaPrint provides a binary classification (low risk or high risk), while Oncotype DX produces a recurrence score on a scale from 0 to 100, broken into low, intermediate, and high ranges. MammaPrint assesses the risk of distant metastasis within 5 to 10 years. The two tests were developed using different gene sets and different patient populations, so they occasionally disagree on risk classification for the same tumor. Your oncologist will typically recommend one based on your specific cancer characteristics and the guidelines they follow.
Cost and Insurance Coverage
MammaPrint is covered by Medicare, with billing codes and coverage criteria established through the MolDX program. Medicare allows the test up to twice per patient lifetime, which accounts for patients with bilateral breast cancer (tumors in both breasts). Most major private insurers also cover the test when it meets clinical criteria, though the specifics of copays and prior authorization vary by plan. If you’re unsure about your coverage, the lab that processes the test can typically verify benefits before it’s run.
What Happens After Testing
Results typically come back within 10 to 12 business days and are sent directly to your oncologist, who will review them alongside your full pathology report, imaging, and clinical history. A low-risk result doesn’t mean cancer treatment is over. Most patients with hormone receptor-positive breast cancer will still take hormone-blocking therapy for five to ten years. What the test determines is whether adding chemotherapy on top of that hormonal treatment is likely to make a difference.
If your result is high risk, your oncologist will discuss a chemotherapy regimen as part of your treatment plan. If it’s low risk, you and your oncologist can feel more confident proceeding with hormone therapy alone, knowing that a rigorous clinical trial supports that decision. Either way, the test converts a difficult, anxiety-laden judgment call into one grounded in the specific biology of your tumor rather than statistical averages.